Köşeci Tolga, Seyyar Mustafa, Aydınalp Camadan Yasemin, Çelik Halil, Mete Burak, Demirhindi Hakan, Eser Kadir, Ata Serdar, Solmaz Ali Alper, Çil Timuçin
Medical Oncology Department, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
Medical Oncology Department, Gaziantep City Hospital, Gaziantep 27470, Türkiye.
Medicina (Kaunas). 2024 Dec 20;60(12):2087. doi: 10.3390/medicina60122087.
: The HALP (Haemoglobin, Albumin, Lymphocyte and Platelet) score is used to predict the prognosis of different types of cancer. This study aimed to investigate the role of the HALP score in predicting pathological response in early-stage gastric cancer patients. : This retrospective cohort study was conducted on 118 patients diagnosed with early-stage gastric cancer and subjected to perioperative (FLOT) treatment between 2018 and 2023. The role of the HALP score in predicting the pathological response to perioperative treatment in patients was investigated. : The mean age of the 118 patients included in the study was 61.3 ± 11.1 (min = 23; max = 86). In the ROC analysis, the optimum cut-off value for the HALP score in pathological response classification was found to be 28.9 (AUC = 0.710, sensitivity = 56.7%, specificity = 80%, PPV = 86.79%, NPV = 46.15%). The pathological response rate was 69% in all patients, 87% in patients with a HALP score ≥ 28.9, and 52% in patients with a HALP score < 28.9 ( < 0.001). The probability of pathological response is 6.5 times higher in patients with a HALP score ≥ 28.9. In the Fagan nomogram, when the HALP score was ≥28.9, our pathological response probability estimate (post-test response probability) was found to increase to 64.8% (Positive Likelihood Ratio = 3, Negative Likelihood Ratio = 0.53). In patients with HALP scores ≥ 28.9 and <28.9, progression rates were 16.7% and 47.8%, respectively ( < 0.001), and median survival times were 45.4 and 30.6 months ( < 0.001). : The HALP score is a useful and easily accessible score for determining pathological responses in patients with locally advanced gastric cancer.
HALP（血红蛋白、白蛋白、淋巴细胞和血小板）评分用于预测不同类型癌症的预后。本研究旨在探讨HALP评分在预测早期胃癌患者病理反应中的作用。：本回顾性队列研究对2018年至2023年间诊断为早期胃癌并接受围手术期（FLOT）治疗的118例患者进行。研究了HALP评分在预测患者围手术期治疗病理反应中的作用。：纳入研究的118例患者的平均年龄为61.3±11.1岁（最小=23岁；最大=86岁）。在ROC分析中，发现HALP评分在病理反应分类中的最佳临界值为28.9（AUC=0.710，敏感性=56.7%，特异性=80%，PPV=86.79%，NPV=46.15%）。所有患者的病理反应率为69%，HALP评分≥28.9的患者为87%，HALP评分<28.9的患者为52%（<0.001）。HALP评分≥28.9的患者病理反应概率高6.5倍。在Fagan列线图中，当HALP评分≥28.9时，我们的病理反应概率估计（检验后反应概率）增加到64.8%（阳性似然比=3，阴性似然比=0.53）。HALP评分≥28.9和<28.9的患者，进展率分别为16.7%和47.8%（<0.001），中位生存时间分别为45.4个月和30.6个月（<0.001）。：HALP评分是确定局部晚期胃癌患者病理反应的有用且易于获得的评分。
